Shares of Novo Nordisk fell sharply after the company announced that its late-stage trial for the heart drug ziltivekimab did not significantly reduce major cardiovascular events like heart attack, stroke, or cardiovascular death compared to a placebo. Although the drug showed some biological activity, it failed to achieve the hoped-for clinical benefits. Novo Nordisk's chief scientific officer emphasized that the company remains committed to cardiovascular disease research despite this setback. The stock dropped about 8.6% in Copenhagen and nearly 10% in U.S. premarket trading.
Anthropic has revealed it operates a wet biology lab where its AI models conduct physical experiments, aiming to bridge AI theories with real-world biology. This lab functions like a typical biotech facility, supporting both in-house research and col...
Novo Nordisk's Phase 3 STEP Young trial demonstrated that weekly semaglutide, combined with lifestyle changes, helped many children aged 6 to under 12 reduce their body mass index below the clinical obesity threshold. Despite this success, the stock ...
